Skip to Content
  • Previous Rank72
  • Revenues ($M)$39,807
  • Revenue Percent Change0.8%
  • Profits ($M)$3,920
  • Profits Percent Change-11.8%
  • Assets ($M)$95,377
  • Employees68,000
  • Market Value — as of March 31, 2017 ($M)$174,454

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, NJ
Websitehttp://www.merck.com
Years on Fortune 500 List23
Employees68,000

Merck Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920-11.8%
Assets ($M)$95,377-
Total Stockholder Equity ($M)$40,088-
Market Value — as of March 31, 2017 ($M)$174,454-

Profit Ratios

Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.41
EPS % Change (from 2015)-9.6%
EPS % Change (5 year annual rate)-6.9%
EPS % Change (10 year annual rate)-3.6%

Total Return

Total Return to Investors (2016)15.1%
Total Return to Investors (5 year, annualized)13.2%
Total Return to Investors (10 year, annualized)7%